Label: MAGNESIUM SULFATE - magnesium sulfate heptahydrate injection, solution

  • DEA Schedule: None
  • Marketing Status: unapproved drug other

DISCLAIMER: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Drug Label Information

Updated August 24, 2010

If you are a consumer or patient please visit this version.

  • Description

    2.03 mM/mL of Magnesium Sulfate Heptahydrate
    Osmolarity 4.06 mOsmol/mL

    Magnesium Sulfate Injection, USP (50%) for IV and IM use is a sterile concentrated solution of Magnesium Sulfate USP. Each mL contains: Magnesium Sulfate (Heptahydrate) 500 mg,
    which provides 4.06 mEq each of Magnesium (Mg++) and Sulfate (SO4 =), Water for Injection q.s. The pH (5.5 - 7.0) is adjusted with Sulfuric Acid and/or Sodium Hydroxide. The solution contains no bacteriostatic agent or other preservatives. The molecular formula is MgSO4 • 7H2O and the molecular weight is 246.47.

  • Clinical Pharmacology

    Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Deficits are accompanied by a variety of structural and functional disturbances.

  • Indications and Usage

    Magnesium Sulfate is indicated in the following conditions:

    Convulsions (treatment) - Intravenous magnesium sulfate is indicated for immediate control of life threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children.

    Hypomagnesemia (prophylaxis and treatment) - Magnesium Sulfate is indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia.

    Magnesium Sulfate is also used to prevent or treat magnesium deficiency in patients receiving total parenteral nutrition.

    Tetany, uterine (treatment) - Magnesium Sulfate is indicated in uterine tetany as a myometrial relaxant.

  • Contraindications

    Magnesium Sulfate should not be administered parenterally in patients with heart block or myocardial damage.

  • Warnings

    Magnesium Sulfate should be given very cautiously in the presence of serious impairment of renal function since it is excreted almost entirely by the kidneys.

    The principle hazard in parenteral magnesium therapy is the production of abnormally high levels of magnesium in the plasma. Such high levels may cause flushing, sweating, hypotension, circulatory collapse and depression of cardiac and central nervous system function. The most immediate danger to life is respiratory depression.

    During the period of parenteral therapy with magnesium salts, the patient should be watched carefully. A preparation of calcium, such as the gluconate or gluceptate should be at hand for intravenous administration as an antidote.

    In the presence of severe renal insufficiency, no more than 20 grams of magnesium should be given within a forty-eight hour period. In eclampsia, however, renal function is not seriously impaired and magnesium may be more rapidly excreted.

    This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

  • Precautions

    When barbiturates, narcotics, or other hypnotics (or systemic anesthetics) are to be given in conjunction with magnesium, their dosage should be adjusted with caution because of the additive
    central depressive effects of magnesium.

    Pregnancy - Teratogenic effects: Pregnancy category C. Animal reproduction studies have not been conducted with Magnesium Sulfate Injection, USP 50%. It is also not known whether
    Magnesium Sulfate Injection, USP 50% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium Sulfate Injection, USP 50% should be given to a pregnant woman only if clearly needed.

  • Adverse Reactions

    Flushing, sweating, sharply lowered blood pressure, hypothermia, stupor and ultimately, respiratory depression.

  • Dosage and Administration

    Intramuscular: Adults and older children: For severe hypomagnesemia, 1 to 5 g (2 to 10 mL of 50% solution) daily in divided doses; administration is repeated daily until serum levels have returned to normal. If deficiency is not severe, 1 g (2 mL of 50% solution) can be given once or twice daily. Serum magnesium levels should serve as a guide to continued dosage.

    Intravenous: 1 to 4 g Magnesium Sulfate may be given intravenously in 10% to 20% solution, but only with great caution; the rate should not exceed 1.5 mL of 10% solution or equivalent per minute until relaxation is obtained.

    Intravenous Infusion: 4 g in 250 mL of 5% Dextrose Injection at a rate not exceeding 3 mL per minute.

    Usual Dose Range: 1 to 40 g daily.

    Electrolyte Replenisher: Intramuscular 1 to 2 g in 50% solution four times a day until serum magnesium is within normal limits.

    Usual Pediatric Dose: Intramuscular 20 to 40 mg per kg of body weight in a 20% solution repeated as necessary.

    For Eclampsia: Initially 1 to 2 g in 25% or 50% solution is given intramuscularly. Subsequently, 1 g is given every 30 minutes until relief is obtained. The blood pressure should be monitored after each injection.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • How Supplied

    Product No.
    Vial Sizes

    NDC 0517-2602-25
    2 mL Single Dose vial
    Boxes of 25
    NDC 0517-2610-25
    10 mL Single Dose vial
    Boxes of 25
    NDC 0517-2650-25
    50 mL Single Dose vial
    Boxes of 2

    Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled Room Temperature).

    Discard unused portion.

    Rev. 1/09
    MG #7879

    SHIRLEY, NY 11967

    Rx Only

  • Sample Outer Label
    magnesium sulfate heptahydrate injection, solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:52584-602(NDC:0517-2602)
    Route of Administration INTRAMUSCULAR, INTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    Magnesium Sulfate Heptahydrate (UNII: SK47B8698T) (Magnesium Cation - UNII:T6V3LHY838) Magnesium Sulfate Heptahydrate 0.5 g  in 1 mL
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:52584-602-25 1 in 1 BAG
    1 2 mL in 1 VIAL, SINGLE-DOSE
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    unapproved drug other 08/01/2010
    Labeler - General Injectables & Vaccines, Inc (108250663)
    Name Address ID/FEI Business Operations
    General Injectables & Vaccines, Inc 108250663 relabel